NAKAMOTO INC

Company Overview

KindlyMD Inc. is a Utah-based outpatient specialty healthcare and healthcare-data company focused on chronic pain, opioid reduction and whole-patient care delivered through owned clinics and telemedicine. Its operating model centers on an Enterprise Data Management (EDM) platform to centralize clinical data and support machine-learning tools, and it reports one of the larger medical-cannabis evaluation footprints in Utah (over 71,751 visits; 20,636 patient visits in 2024). The company is undergoing a strategic shift from cash-pay and retail product sales toward in-network payer billing (Medicare/Medicaid and commercial) and has recently invested in data infrastructure while navigating significant regulatory oversight and capital needs. Recent financials show revenue pressure (2024 revenue down 27.8% to $2.72M) and widening losses as management repositions the business and pursues a transformative merger and bitcoin treasury strategy in 2025.

Executive Compensation Practices

Compensation at KindlyMD is likely influenced by a mix of healthcare operational and financing metrics: payer contract wins and reimbursement rates, patient visit growth and retention, de-prescribing and behavioral-health outcomes, and successful deployment of the EDM platform. The company already records material stock-based compensation (valuation under Black–Scholes is a key accounting judgment) and has increased G&A and D&O costs since becoming public, which makes equity-heavy packages and option/RSU grants a likely tool to conserve cash while aligning executives to longer-term value creation. Given ongoing losses, limited free cash flow and recent capital raises (IPO proceeds ≈ $5.9M, substantial warrant and PIPE activity), expect emphasis on equity incentives, milestone-based awards tied to payer-network expansion, and retention bonuses to retain clinical and data talent. The pending merger, convertible debenture proposals and digital-asset strategy may create additional milestone or transaction-related payouts that dilute shareholders and materially affect executive realized compensation.

Insider Trading Considerations

Insider trading patterns at KindlyMD should be monitored around specific, company‑sensitive events: announcements of payer contracts or in‑network status, clinic openings/closures, material EDM or data-licensing agreements, regulatory developments around cannabis/hemp, and merger/financing milestones tied to the Nakamoto/bitcoin strategy. The firm’s recent IPO, warrant exercises, PIPEs, convertible debenture proposals and substantial purchases of bitcoin introduce atypical market-moving events and volatility that could increase scrutiny of insider trades; insiders trading near these financings or digital-asset disclosures may attract regulatory attention. Standard safeguards—Section 16 filings, 10b5-1 plans, post‑IPO/transaction lockups and blackout windows around earnings and material disclosures—are particularly relevant here, and researchers should watch for equity grants and option exercises that precede large share sales or financing announcements.